Oruka Therapeutics, Inc. Common Stock (ORKA) Financials

Key financial figures for Oruka Therapeutics, Inc. Common Stock (Q2 2026).

Oruka Therapeutics reported a Q2 2026 net loss of $41.2 million as R&D spend rose to $43.3 million, ending the quarter with $1.1 billion in cash, cash equivalents and marketable securities. R&D expenses were $43.3 million in Q2 2026, up from $24.1 million in Q2 2025, driven by additional clinical trial costs, a non-refundable upfront payment to Halozyme, and higher headcount-related compensation. G&A expenses were $6.9 million, up from $4.3 million a year earlier, on employee compensation and public-company operating costs. Loss from operations was $50.1 million and net loss was $41.2 million ($0.55 per share), versus a $28.4 million operating loss and $24.6 million net loss ($0.46 per share) in Q2 2025. On the outlook: No formal quarterly or annual financial guidance was issued. The company states its cash, cash equivalents, and marketable securities are expected to be sufficient to fund operations through an anticipated BLA filing for ORKA-001 and continued development of ORKA-002, with no specific runway date given in quarters or months. Figures are for Q2 2026, as Oruka Therapeutics, Inc. reported them.

Revenue

$0

Net Income

-$41M

Total Assets

$1.1B

Operating Cash Flow

-$33M

Full income statement, balance sheet and cash flow for Oruka Therapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.